Summary | |
---|---|
Symbol | FOXC2 |
Name | forkhead box C2 |
Aliases | MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ...... |
Chromosomal Location | 16q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus |
Domain |
PF00250 Forkhead domain |
Function |
Transcriptional activator. Might be involved in the formation of special mesenchymal tissues. |
Biological Process |
GO:0001501 skeletal system development GO:0001503 ossification GO:0001525 angiogenesis GO:0001569 patterning of blood vessels GO:0001654 eye development GO:0001655 urogenital system development GO:0001656 metanephros development GO:0001657 ureteric bud development GO:0001667 ameboidal-type cell migration GO:0001704 formation of primary germ layer GO:0001707 mesoderm formation GO:0001710 mesodermal cell fate commitment GO:0001756 somitogenesis GO:0001763 morphogenesis of a branching structure GO:0001822 kidney development GO:0001823 mesonephros development GO:0001945 lymph vessel development GO:0001946 lymphangiogenesis GO:0001974 blood vessel remodeling GO:0002040 sprouting angiogenesis GO:0002042 cell migration involved in sprouting angiogenesis GO:0002064 epithelial cell development GO:0003002 regionalization GO:0003007 heart morphogenesis GO:0003013 circulatory system process GO:0003018 vascular process in circulatory system GO:0003151 outflow tract morphogenesis GO:0003158 endothelium development GO:0003205 cardiac chamber development GO:0003206 cardiac chamber morphogenesis GO:0003208 cardiac ventricle morphogenesis GO:0003229 ventricular cardiac muscle tissue development GO:0003231 cardiac ventricle development GO:0003275 apoptotic process involved in outflow tract morphogenesis GO:0003278 apoptotic process involved in heart morphogenesis GO:0007219 Notch signaling pathway GO:0007369 gastrulation GO:0007389 pattern specification process GO:0007423 sensory organ development GO:0007498 mesoderm development GO:0007507 heart development GO:0007517 muscle organ development GO:0008015 blood circulation GO:0008286 insulin receptor signaling pathway GO:0009952 anterior/posterior pattern specification GO:0010594 regulation of endothelial cell migration GO:0010595 positive regulation of endothelial cell migration GO:0010631 epithelial cell migration GO:0010632 regulation of epithelial cell migration GO:0010634 positive regulation of epithelial cell migration GO:0014031 mesenchymal cell development GO:0014032 neural crest cell development GO:0014033 neural crest cell differentiation GO:0014706 striated muscle tissue development GO:0014855 striated muscle cell proliferation GO:0030198 extracellular matrix organization GO:0030199 collagen fibril organization GO:0030335 positive regulation of cell migration GO:0032835 glomerulus development GO:0032868 response to insulin GO:0032869 cellular response to insulin stimulus GO:0033002 muscle cell proliferation GO:0033627 cell adhesion mediated by integrin GO:0033628 regulation of cell adhesion mediated by integrin GO:0033630 positive regulation of cell adhesion mediated by integrin GO:0035050 embryonic heart tube development GO:0035150 regulation of tube size GO:0035239 tube morphogenesis GO:0035265 organ growth GO:0035282 segmentation GO:0035470 positive regulation of vascular wound healing GO:0035850 epithelial cell differentiation involved in kidney development GO:0036303 lymph vessel morphogenesis GO:0040017 positive regulation of locomotion GO:0043010 camera-type eye development GO:0043062 extracellular structure organization GO:0043434 response to peptide hormone GO:0043534 blood vessel endothelial cell migration GO:0043535 regulation of blood vessel endothelial cell migration GO:0043536 positive regulation of blood vessel endothelial cell migration GO:0043542 endothelial cell migration GO:0045165 cell fate commitment GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0045785 positive regulation of cell adhesion GO:0046620 regulation of organ growth GO:0048010 vascular endothelial growth factor receptor signaling pathway GO:0048332 mesoderm morphogenesis GO:0048333 mesodermal cell differentiation GO:0048339 paraxial mesoderm development GO:0048340 paraxial mesoderm morphogenesis GO:0048341 paraxial mesoderm formation GO:0048342 paraxial mesodermal cell differentiation GO:0048343 paraxial mesodermal cell fate commitment GO:0048514 blood vessel morphogenesis GO:0048562 embryonic organ morphogenesis GO:0048568 embryonic organ development GO:0048638 regulation of developmental growth GO:0048644 muscle organ morphogenesis GO:0048701 embryonic cranial skeleton morphogenesis GO:0048703 embryonic viscerocranium morphogenesis GO:0048704 embryonic skeletal system morphogenesis GO:0048705 skeletal system morphogenesis GO:0048706 embryonic skeletal system development GO:0048738 cardiac muscle tissue development GO:0048754 branching morphogenesis of an epithelial tube GO:0048762 mesenchymal cell differentiation GO:0048771 tissue remodeling GO:0048844 artery morphogenesis GO:0048863 stem cell differentiation GO:0048864 stem cell development GO:0050880 regulation of blood vessel size GO:0051272 positive regulation of cellular component movement GO:0055008 cardiac muscle tissue morphogenesis GO:0055010 ventricular cardiac muscle tissue morphogenesis GO:0055017 cardiac muscle tissue growth GO:0060038 cardiac muscle cell proliferation GO:0060055 angiogenesis involved in wound healing GO:0060415 muscle tissue morphogenesis GO:0060419 heart growth GO:0060485 mesenchyme development GO:0060537 muscle tissue development GO:0060561 apoptotic process involved in morphogenesis GO:0060562 epithelial tube morphogenesis GO:0060795 cell fate commitment involved in formation of primary germ layer GO:0060840 artery development GO:0061005 cell differentiation involved in kidney development GO:0061041 regulation of wound healing GO:0061042 vascular wound healing GO:0061043 regulation of vascular wound healing GO:0061053 somite development GO:0061138 morphogenesis of a branching epithelium GO:0061318 renal filtration cell differentiation GO:0061437 renal system vasculature development GO:0061440 kidney vasculature development GO:0061448 connective tissue development GO:0071375 cellular response to peptide hormone stimulus GO:0071417 cellular response to organonitrogen compound GO:0072001 renal system development GO:0072006 nephron development GO:0072007 mesangial cell differentiation GO:0072008 glomerular mesangial cell differentiation GO:0072009 nephron epithelium development GO:0072010 glomerular epithelium development GO:0072011 glomerular endothelium development GO:0072012 glomerulus vasculature development GO:0072073 kidney epithelium development GO:0072109 glomerular mesangium development GO:0072112 glomerular visceral epithelial cell differentiation GO:0072132 mesenchyme morphogenesis GO:0072143 mesangial cell development GO:0072144 glomerular mesangial cell development GO:0072163 mesonephric epithelium development GO:0072164 mesonephric tubule development GO:0072311 glomerular epithelial cell differentiation GO:0090049 regulation of cell migration involved in sprouting angiogenesis GO:0090050 positive regulation of cell migration involved in sprouting angiogenesis GO:0090066 regulation of anatomical structure size GO:0090130 tissue migration GO:0090132 epithelium migration GO:0090303 positive regulation of wound healing GO:1901342 regulation of vasculature development GO:1901652 response to peptide GO:1901653 cellular response to peptide GO:1902256 regulation of apoptotic process involved in outflow tract morphogenesis GO:1902257 negative regulation of apoptotic process involved in outflow tract morphogenesis GO:1902337 regulation of apoptotic process involved in morphogenesis GO:1902338 negative regulation of apoptotic process involved in morphogenesis GO:1902742 apoptotic process involved in development GO:1903034 regulation of response to wounding GO:1903036 positive regulation of response to wounding GO:1903670 regulation of sprouting angiogenesis GO:1903672 positive regulation of sprouting angiogenesis GO:1904018 positive regulation of vasculature development GO:1904238 pericyte cell differentiation GO:1904746 negative regulation of apoptotic process involved in development GO:1904748 regulation of apoptotic process involved in development GO:1904888 cranial skeletal system development GO:2000027 regulation of organ morphogenesis GO:2000147 positive regulation of cell motility GO:2000826 regulation of heart morphogenesis |
Molecular Function |
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003682 chromatin binding GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0031490 chromatin DNA binding GO:0043566 structure-specific DNA binding |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | FOXC2 |
Name | forkhead box C2 |
Aliases | MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ...... |
Chromosomal Location | 16q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between FOXC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | FOXC2 |
Name | forkhead box C2 |
Aliases | MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ...... |
Chromosomal Location | 16q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of FOXC2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | FOXC2 |
Name | forkhead box C2 |
Aliases | MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ...... |
Chromosomal Location | 16q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of FOXC2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of FOXC2 in various data sets.
|
Summary | |
---|---|
Symbol | FOXC2 |
Name | forkhead box C2 |
Aliases | MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ...... |
Chromosomal Location | 16q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOXC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | FOXC2 |
Name | forkhead box C2 |
Aliases | MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ...... |
Chromosomal Location | 16q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOXC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOXC2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | FOXC2 |
Name | forkhead box C2 |
Aliases | MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ...... |
Chromosomal Location | 16q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOXC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | FOXC2 |
Name | forkhead box C2 |
Aliases | MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ...... |
Chromosomal Location | 16q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of FOXC2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | FOXC2 |
Name | forkhead box C2 |
Aliases | MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ...... |
Chromosomal Location | 16q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between FOXC2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | FOXC2 |
Name | forkhead box C2 |
Aliases | MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ...... |
Chromosomal Location | 16q24.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting FOXC2 collected from DrugBank database. |
There is no record. |